South Korea’s JW Pharmaceutical Corp. Wednesday unveiled data from an ongoing phase 2a clinical study that showed its investigational gout drug URC102 effectively lowered uric acid levels in the blood.
The novel drug being co-developed with Japan`s Chugai Pharmaceutical Co. is designed to promote the discharge of uric acid in the renal tubules. Excess uric acid builds up and gets deposited on the joints in about 90 percent of gout patients.
JW Pharm said a significant reduction in plasma uric acid concentration was demonstrated in the latest clinical study involving 140 gout patients at 14 hospitals including Hanyang University Medical Center and Seoul National University Hospital across Korea. There were no newly reported adverse events in the previous and current study.
The study findings were presented at the 2017 American College of Rheumatology`s Annual Meeting held November 3 to 8 in San Diego, California.
Shares of JW Pharm Thursday closed 1.14 percent down at 47,850 won from the previous session.
By Kim Hye-soon and Minu Kim
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]